Krista Lachance and Rima Kulikauskas (Seattle, WA, USA)
How can the Merkel cell carcinoma collaborative (MC3) Institute help advance our field? 

Brendan McCann (Glasgow, Scotland, UK)
Scottish Clinical Management Guidelines for MCC

Candice Church (Seattle, WA, USA)
Understanding the Merkel cell polyomavirus TCRome as a future tool for monitoring immune studies and immunotherapy

Sara Passerini (Rome, Italy)
Merkel Cell Polyomavirus (MCPyV) and the DNA Damage Response (DDR): Expression Analysis of DDR Genes in MCPyV-positive Merkel Cell Carcinoma and in Human Dermal Fibroblasts

Xiaohao Wang (Stockholm, Sweden)
Title TBD 

Büke Celikdemir (Turkey)
Title TBD

Peter Ch’en (Seattle, WA, USA)
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant MCC: a rationale for future clinical trials